market price sensitive information, page-3

just reading through the announcement...
Initial highlights are...

Stirling Products is currently in advanced negotiation for:
• acquisition of a $30 million near new, fully licensed pharmaceutical production facility on extra-ordinary terms
• over $5 million in government grants
…. and positioned for:
• significant sales revenues – commencing next 3 – 6 months
• targeted cash flow breakeven by mid 2010
• targeted annualised sales revenue of min $30M by end 2010

The market for herbal and botanical products is forecast to grow by over 168% over the next 5 years to over US$33 billion
• Over 60% of all New Chemical Entities for prescription pharmaceuticals in the last 5 years have been derived from natural or synthesized natural sources

ImmunoXel has demonstrated in all its clinical trials that it:
• is a powerful immunomodulator and adjuvant
• substantively tunes the Immune System
• enhances efficacy of - antibiotics, viral therapies
and chemotherapies
• can substantially shorten drug and chemotherapy
treatment duration
• can reduce and reverse treatment toxicity
side-effects – esp. in liver and kidneys
• is market ready for treatment of TB, TB/HIV, AIDS
• over 800 patients treated in clinical trials
– mainly TB, TB/HIV but also AIDS and influenza

• Enhances efficacy of drugs 2-10 fold
• Shortens therapy duration 3-12 fold
• Reduces and reverses toxicity of current TB drugs

World Health Organisation estimates (2007) over 1 million people in each of India and China have TB ( page 15)

Estimated Number of People Living with HIV/AIDS,(2007) over 30 million ( page 17)

There are plenty more pages of info in the presentation that I expect will spark some interest in India